Company

Immunophotonics is a private biotechnology company that is developing a proprietary carbohydrate polymer (IP-001) for use after a common tumor ablation procedure to induce a systemic anti-tumor immune response. Immunophotonics has subsidiaries in Bern, Switzerland and Tianjin, China. We are a multidisciplinary team of highly experienced individuals committed to pioneering the future of cancer immunotherapy.

TEAM

  Tomas Hode,  Ph.D.  CEO

Tomas Hode,  Ph.D.
CEO

  Lu Alleruzzo, MBA  COO & President

Lu Alleruzzo, MBA
COO & President

  Joseph Raker, Ph.D.  Chief Drug Dev. Officer

Joseph Raker, Ph.D.
Chief Drug Dev. Officer

  Theresa Visarius, Ph.D.  VP Business Dev.

Theresa Visarius, Ph.D.
VP Business Dev.

 
  Siu Kit Lam, Ph.D.  VP Science & Research

Siu Kit Lam, Ph.D.
VP Science & Research

  Troy Jiao, MFE  VP Asian Business Dev.

Troy Jiao, MFE
VP Asian Business Dev.

  Monica Croke, Ph.D.  Clinical Consultant

Monica Croke, Ph.D.
Clinical Consultant

 

Board

  Bobby Sandage, Ph.D.  Chairman

Bobby Sandage, Ph.D.
Chairman

  Charlie Bolten  Biogenerator

Charlie Bolten
Biogenerator

  David Smoller, Ph.D.  Cultivation Capital

David Smoller, Ph.D.
Cultivation Capital

  Robert Nordquist, Ph.D.  Inventor

Robert Nordquist, Ph.D.
Inventor

 
  Wei Chen, Ph.D.  Inventor

Wei Chen, Ph.D.
Inventor

  Tomas Hode, Ph.D.  CEO

Tomas Hode, Ph.D.
CEO

  Lu Alleruzzo, MBA  COO & President

Lu Alleruzzo, MBA
COO & President

 

Advisors

  Mark Naylor, M.D.  Clinical Development

Mark Naylor, M.D.
Clinical Development

  Michael Hamblin, Ph.D.  Non-clinical Development

Michael Hamblin, Ph.D.
Non-clinical Development

  Grant Williams, M.D.  Regulatory Strategy

Grant Williams, M.D.
Regulatory Strategy

  Daniel Von Hoff, M.D.  Clinical Development

Daniel Von Hoff, M.D.
Clinical Development

 
  Richard Levenson, M.D.  Clinical Development

Richard Levenson, M.D.
Clinical Development

  John Weatherspoon  J.D./Ph.D. IP Protection

John Weatherspoon
J.D./Ph.D.
IP Protection

  David W. Anderson, Ph.D.  Non-clinical Development  

David W. Anderson, Ph.D.
Non-clinical Development